ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

05 янв 2022 08:00:01 Источник Nasdaq GlobeNewswire

Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

03 янв 2022 16:01:00 Источник Nasdaq GlobeNewswire

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

01 дек 2021 16:30:00 Источник Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

01 дек 2021 08:00:01 Источник Nasdaq GlobeNewswire

Ultragenyx to Present at Evercore 4th Annual HealthconX Conference

29 ноя 2021 16:40:38 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies

29 ноя 2021 08:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update

02 ноя 2021 16:05:03 Источник Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update

26 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

25 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

18 окт 2021 08:00:01 Источник Nasdaq GlobeNewswire